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Recent genome-wide association studies (GWAS) have identiﬁed multiple risk loci for common obesity (FTO,
MC4R, TMEM18, GNPDA2, SH2B1, KCTD15, MTCH2, NEGR1 and PCSK1). Here we extend those studies by
examining associations with adiposity and type 2 diabetes in Swedish adults. The nine single nucleotide
polymorphisms (SNPs) were genotyped in 3885 non-diabetic and 1038 diabetic individuals with available
measures of height, weight and body mass index (BMI). Adipose mass and distribution were objectively
assessed using dual-energy X-ray absorptiometry in a sub-group of non-diabetics (n 5 2206). In models
with adipose mass traits, BMI or obesity as outcomes, the most strongly associated SNP was FTO
rs1121980 (P < 0.001). Five other SNPs (SH2B1 rs7498665, MTCH2 rs4752856, MC4R rs17782313, NEGR1
rs2815752 and GNPDA2 rs10938397) were signiﬁcantly associated with obesity. To summarize the overall
genetic burden, a weighted risk score comprising a subset of SNPs was constructed; those in the top quintile
of the score were heavier (12.6 kg) and had more total (12.4 kg), gynoid (1191 g) and abdominal (1136 g)
a d i p o s et i s s u et h a nt h o s ei nt h el o w e s tq u i n t i l e( a l lP < 0.001). The genetic burden score signiﬁcantly
increased diabetes risk, with those in the highest quintile (n 5 193/594 cases/controls) being at 1.55-fold
(95% CI 1.21–1.99; P < 0.0001) greater risk of type 2 diabetes than those in the lowest quintile (n 5 130/655
cases/controls). In summary, we have statistically replicated six of the previously associated obese-risk
loci and our results suggest that the weight-inducing effects of these variants are explained largely by
increased adipose accumulation.
INTRODUCTION
Obesity is a major global health burden with a multitude of
co-morbidities including type 2 diabetes, cardiovascular
disease, certain cancers, sleep apnea, and osteoarthritis (1).
Although the current obesity epidemic is likely related to
decreased habitual physical activity levels and changes in
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factors also affect the predisposition to obesity (2). While
several monogenic causes of obesity have been well-described
during the past decade, the progress in deﬁning the genetic
basis of common obesity had been frustratingly slow prior to
2007; since then, obesity-predisposing variants in the FTO
(3), MC4R (4,5), TMEM18, GNPDA2, SH2B1, KCTD15,
MTCH2, NEGR1 (6) and PCSK1 (7) genes have emerged.
All of these studies focused primarily on anthropometric
measures of obesity, such as body mass index (BMI) or bioim-
pedance, with none having described associations with objec-
tively assessed adipose distribution.
The purpose of the present study was to attempt to replicate
the previously reported genetic associations with obesity in
ethnically homogeneous cohorts from northern Sweden. We
also sought to extend previous studies by examining genotype
associations singly and in combination with measures of
adipose mass, adipose distribution and type 2 diabetes.
RESULTS
Table 1 shows participant characteristics for the different
cohorts studied here.
Genotype associations with measures of body composition
and adipose distribution (continuous trait models)
Table 2 summarizes the adjusted mean level of BMI for each
SNP. Six of the nine variants were statistically associated with
BMI, with one additional SNP approaching statistical signiﬁ-
cance. The SNP most strongly associated with BMI localized
to the FTO gene (rs1121980) (P , 0.0001). The MC4R
rs17782313 SNP statistically interacted with sex (P ¼ 0.02),
whereby the minor allele was associated with higher
BMI in women (b ¼ 0.41 kg/m
2 per copy of the minor
allele; P ¼ 0.0034), but no effect was observed in men
(b ¼ 2 0.03 kg/m
2 per copy of the minor allele; P ¼ 0.83).
Similar interaction effects were observed for total
(P ¼ 0.024) and abdominal (P ¼ 0.046) adipose mass.
The FTO SNP (rs1121980) was also strongly associated
with total, abdominal and gynoid adipose mass (Table 3). As
in earlier studies (3), the per allele increase in weight for
FTO rs1121980 was 1.03 kg (P ¼ 0.005), of which 0.91 kg
was attributable to increased total adipose mass (P ¼
0.0007). As shown in Table 3, although trends for association
with measures of adiposity were evident for several of the
remaining SNPs in directions consistent with the associations
with obesity, only three reached a formal level of statistical
signiﬁcance (FTO, MTCH2 and GNPDA2). Figure 1 shows
the absolute weight difference between major and minor
allele homozygotes at each of the obesity-associated loci and
between the ﬁrst and ﬁfth quintiles of the genetic burden
score (GBS). The ﬁgure also illustrates how much of the
total weight difference between genotypes at a given locus
is attributable to adipose accumulation. When the overall con-
tribution of these SNPs was assessed using the GBS, strong
associations were evident for all anthropometric (Fig. 2A
and B) and dual-energy X-ray absorptiometry (DEXA)
measures of obesity (Fig. 2C–E). For example, when stratiﬁed
into quintiles, those with the highest level of the GBS (Q5)
weighed approximately 2.56 kg more than those with the
lowest level of the GBS (Q1) (b ¼ 0.87 kg per SD increase
in score, P , 0.0001). Consistently, BMI was 0.97 kg/m
2
higher (b ¼ 0.32 kg/m
2 per SD increase in the score, P ,
0.0001), total adipose mass was 2.41 kg higher (b ¼ 0.76 kg
per SD increase in the score, P ¼ 0.0001), abdominal
adipose mass was 0.14 kg higher (b ¼ 0.04 kg per SD increase
in the score, P ¼ 0.0004), and gynoid adipose mass was
0.19 kg higher (b ¼ 0.06 kg per SD increase in the score,
P ¼ 0.0002) in the top versus bottom quintiles of the GBS.
Genotype associations with obesity (categorical
trait models)
The following results are derived from the cohort of non-
diabetic individuals only (n ¼ 3885). Table 4 shows obesity
risk estimates (odds ratios; OR) for each of the genetic predic-
tor variables ranked by magnitude of effect in non-diabetics.
As with the BMI models reported above, the FTO
rs1121980 variant was the most strongly associated SNP,
with a per allele OR of 1.15 (95% CI 1.05–1.25; P ¼
0.0016). Five of the remaining SNPs (SH2B1, MTCH2,
MC4R, NEGR1 and GNPDA2) were signiﬁcantly associated
with obesity in directions consistent with prior reports of
association with BMI (6–8). For the GBS, the risk of
obesity increased by 1.13 (95% CI 1.06–1.21; P ¼ 0.0002)
per SD unit increase, with a 1.40-fold (95% CI 1.14–1.72;
P ¼ 0.002) increased risk of being obese for those in the top
compared with the bottom quintiles of the score. One SNP
(MC4R rs17782313) statistically interacted with sex (P ¼
0.02), whereby the minor allele was associated with increased
obesity risk in women (OR ¼ 1.20; 95% CI 1.06–1.36;
P ¼ 0.0034), but no effect was observed in men (OR ¼ 0.94;
95% CI 0.79–1.12; P ¼ 0.48).
Comparison of genetic effects on obesity receiver-
operating characteristic curves (ROCAUC models)
The power of each of the SNPs to discriminate between normal
weight and obese individuals [i.e. the receiver-operating
Table 1. Participant characteristics
Variable All non-diabetic
individuals, n or
mean (SD)
Diabetic
individuals, n
or mean (SD)
Non-diabetic
individuals with
body scans, n or
mean (SD)
Sex (n ¼ M/F) 1391/2494 609/429 516/1690
Age (years) 52.6 (9.5) 53.8 (7.3) 52.2 (10.3)
Height (m) 1.68 (0.09) 1.71 (0.10) 1.67 (0.09)
Weight (kg) 73.2 (13.5) 88.4 (14.7) 71.8 (13.5)
Body mass index
(kg/m
2)
25.7 (4.0) 30.4 (4.7) 25.6 (4.1)
Total adipose mass
(kg)
– – 25.1 (9.2)
Abdominal adipose
mass (kg)
– – 1.52 (0.54)
Gynoid adipose
mass (kg)
– – 2.53 (0.83)
Total lean mass (kg) – – 44.2 (9.9)
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discriminative power of the GBS as the criterion variable
(Table 4). The crude ROCAUC for the GBS was 0.5752
(Fig. 3) (P , 0.0001). This compared with a ROCAUC of
0.5881 (P , 0.0001) when all eight SNPs were entered
simultaneously into the ROC model. The combination of all
SNPs was a signiﬁcantly more powerful discriminator than
any single SNP, with or without adjustment for age and sex
(P , 0.05). The FTO variant was the most discriminative of
the individual SNPs (crude ROCAUC ¼ 0.5435; P , 0.0001),
with the crude ROCAUCs ranging from 0.5087 to 0.5348 for
the remaining SNPs.
Genetic effects on risk of type 2 diabetes
Table 5 shows the associations between each of the nine
obesity-risk variants and type 2 diabetes. In models adjusted
for age and sex, four variants were signiﬁcantly associated
with type 2 diabetes risk (FTO rs1121980: P ¼ 0.013;
MC4R rs17782313: P ¼ 0.009; GNPDA2 rs10938397: P ¼
0.028; TMEM18 rs6548238: P ¼ 0.007). A tendency for
association with diabetes was observed for the SH2B1
rs7498665 variant (P ¼ 0.06). After additional adjustment
for BMI, none remained statistically signiﬁcant. Although
PCSK1 rs6235 was not signiﬁcantly associated with diabetes
in the age- and sex-adjusted models (P ¼ 0.21), additional
adjustment for BMI rendered a nominally signiﬁcant protec-
tive effect for this variant (P ¼ 0.04).
The risk of type 2 diabetes was signiﬁcantly increased
across the spectrum of the GBS following adjustment for
age and sex (linear P , 0.0001). For each SD unit increase
in the score, the risk of diabetes increased signiﬁcantly
(OR ¼ 1.17; 95% CI 1.09–1.27), with those in the highest
quintile of the GBS (n ¼ 193/594 cases/controls) being at
1.55 (95% CI 1.21–1.99) greater risk of type 2 diabetes than
those in the lowest quintile (n ¼ 130/655 cases/controls).
When all SNPs were simultaneously entered into the model,
the unadjusted ROCAUC for type 2 diabetes was 0.5643
(P , 0.0001), which was signiﬁcantly larger than any of the
individual SNP ROCAUCs. The ROCAUC for the GBS was
0.5524, which did not differ from the model containing all
SNPs (P difference ¼ 0.14). Additional adjustment for BMI
attenuated the association, with those in the highest quintile
of the score no longer being at signiﬁcantly greater risk of dia-
betes relative to those in the lowest quintile (OR 1.22; 95% CI
0.92–1.62). The ROCAUC for the model including age and
sex (ROCAUCs ¼ 0.6382) improved signiﬁcantly when the
nine SNPs were added to the model (ROCAUCs ¼ 0.6654)
Table 3. Effect estimates and P-values for tests of association between nine purported obesity-risk variants and adipose traits measured using DEXA (n ¼ 2206)
Nearest gene SNP Total adipose mass (kg) Abdominal adipose mass
(kg)
Gynoid adipose mass (kg)
b P-value b P-value b P-value
FTO rs1121980 0.91 0.0007 0.05 0.0008 0.07 0.004
SH2B1 rs7498665 0.32 0.24 0.02 0.17 0.03 0.28
MTCH2 rs4752856 0.38 0.16 0.03 0.04 0.04 0.12
MC4R rs17782313 0.46 0.15 0.02 0.20 0.02 0.36
NEGR1 rs2815752 0.23 0.41 0.02 0.14 0.03 0.18
GNPDA2 rs10938397 0.44 0.12 0.03 0.06 0.05 0.05
TMEM18 rs6548238 0.30 0.38 0.00 0.91 0.03 0.32
KCTD15 rs11084753 0.07 0.80 0.00 0.92 0.02 0.51
PCSK1 rs6235 0.15 0.62 0.00 0.95 0.01 0.62
GBS (SD units) – 0.76 0.0001 0.04 0.0004 0.06 0.0002
bIndicates thedifference inadipose mass per copy of the riskallele at each locus. Data are from separate generalized linearmodels, assuming an additive
mode of genetic inheritance and adjusted for age and sex. GBS ¼ genetic burden score.
Table 2. Adjusted mean body mass index (BMI) for nine purported obesity-risk variants in non-diabetic individuals (n ¼ 3885)
Nearest gene SNP Risk allele (frequency) Adjusted means (95% CI) by genotype P-value
MM Mm mm
FTO rs1121980 A (0.42) 25.3 (25.1–25.6) 25.8 (25.6–26.0) 26.1 (25.8–26.4) ,0.0001
SH2B1 rs7498665 C (0.40) 26.0 (25.7–26.3) 25.8 (25.6–26.0) 25.4 (25.2–25.6) 0.0006
MTCH2 rs4752856 T (0.37) 25.5 (25.3–25.7) 25.8 (25.6–26.0) 25.9 (25.5–26.2) 0.025
MC4R rs17782313 C (0.26) 25.6 (25.4–25.7) 25.8 (25.6–26.0) 26.2 (25.7–26.6) 0.013
NEGR1 rs2815752 A (0.58) 25.5 (25.2–25.8) 25.6 (25.4–25.8) 25.9 (25.7–26.1) 0.023
GNPDA2 rs10938397 G (0.37) 25.6 (25.4–25.8) 25.7 (25.5–25.9) 26.0 (25.7–26.4) 0.068
TMEM18 rs6548238 A (0.82) 25.8 (25.6–25.9) 25.6 (25.3–25.8) 25.2 (24.5–25.8) 0.049
KCTD15 rs11084753 G (0.63) 25.7 (25.5–25.9) 25.7 (25.5–25.9) 25.6 (25.2–25.9) 0.472
PCSK1 rs6235 C (0.30) 25.7 (25.5–25.9) 25.7 (25.5–25.9) 25.8 (25.4–26.3) 0.588
M ¼ major allele; m ¼ minor allele; SNP ¼ single nucleotide polymorphism. Means are adjusted for age and sex. P-values are from linear models
assuming an additive mode of genetic inheritance.
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power attributable to the SNPs (ROCAUCs: age, sex and
BMI ¼ 0.8236 versus age, sex, BMI and SNPs ¼ 0.8236).
DISCUSSION
In this study we examined the associations of nine recently
discovered obesity loci with anthropometric and DEXA-
derived measures of adipose mass, adipose distribution and
type 2 diabetes risk in adults from northern Sweden. The pre-
viously reported genetic associations for these variants with
obesity replicated for six loci. To assess the overall burden
conveyed by the variants, we composed a weighted genetic
risk score and show that this is strongly associated with
obesity and the accumulation of total, abdominal and gynoid
adipose tissue. Because obesity is an established risk factor
for type 2 diabetes, it is important to determine whether the
increased genetic predisposition to obesity translates to
increased type 2 diabetes risk, which we were able to
conﬁrm for several variants. All associated variants clearly
conveyed their effects via obesity.
During the past two decades, a great number of studies have
been published purporting to have identiﬁed gene variants that
predispose to obesity [as summarized in (9)].The credibility
and relevance of these studies is indicated by the success of
replication attempts within and beyond the geographic and
ethnic groups from which the original reports hailed. Unfortu-
nately, very few of these earlier reports have been adequately
replicated. Thus, the identiﬁcation of the FTO locus in 2007
(3) and the subsequent discovery of several other genetic
risk factors for obesity (4–7) marked an important break-
through in comprehending the genetic basis of common
obesity. However, the extension of the initial studies’ ﬁndings
to more detailed and complex disease phenotypes is necessary
if the clinical relevance of genetic variation is to be ascer-
tained. Figure 1 illustrates the total difference in body mass
between major and minor allele homozygotes at each of the
obesity-associated loci, with the weight difference attributable
to total, abdominal and gynoid adipose tissue overlaid. While
these data illustrate that the weight differences observed for all
of the variants are largely related to increased adiposity, for
some loci fairly large proportions of the weight difference
between homozygotes is attributable to lean mass. For
example, the FTO, MCTH2 and TMEM18 variants were pre-
dominantly associated with adipose accumulation, whereas
the variances in weight for the SH2B1 and NEGR1 variants
appear to be explained to a larger extent by the accumulation
of non-adipose tissue (e.g. bone, muscle and organ tissue).
These characteristics may be of relevance when considering
the importance of these variants in cardiovascular and meta-
bolic disease etiology. This is because the health risks associ-
ated with weight gain vary depending on whether fat or lean
tissue is the source of the accumulated weight.
For one variant (MC4R rs17782313), nominally signiﬁcant
interactions with sex were observed, where the associations
between the genotypes and obesity measures were consistent
with prior reports in females, but were inconclusive in
males. None of the interaction P-values was robust to cor-
rection for multiple statistical comparisons, suggesting that
these observations may be false-positive. Furthermore, no
prior evidence of sex-effects at this locus has been reported.
Nonetheless, it is important to highlight that some individ-
uals in this cohort who underwent DEXA scans did so
because they were athletes, had sustained recent injuries,
or were concerned about skeletal health (10). Whether differ-
Figure 1. Differences in weight (kg) and total, abdominal and gynoid adipose mass (kg) between major and minor allele homozygotes at each of the seven
nominally associated loci (P , 0.1) and between the ﬁrst and ﬁfth quintiles of the genetic burden score. Data are adjusted for age and sex (n ¼ 2206). As
described in the results, nominal gene–sex interactions were observed for total and abdominal adipose mass at the MC4R locus.
1492 Human Molecular Genetics, 2009, Vol. 18, No. 8Figure 2. Associations between the genetic burden score (expressed in quintiles) and obesity indices. Error bars are 95% conﬁdence intervals. P-values are
derived from linear regression models adjusted for age and sex. (A) P ¼ 2.32   10
25;( B) P ¼ 3.69   10
26;( C) P ¼ 0.0001; (D) P ¼ 0.0004; (E) P ¼
0.0002; (F) P ¼ 0.099).
Table 4. Estimates of obesity risk (odds ratios) and discriminative power (ROCAUCs) for nine purported obesity-risk variants singly and in combination in
non-diabetic individuals (n ¼ 3885)
Nearest gene SNP Risk allele (frequency) OR 95% CI P ROCAUC PROCAUC
FTO rs1121980 A (0.42) 1.15 (1.05–1.25) 0.002 0.5435 2.00   10
24
SH2B1 rs7498665 C (0.40) 1.13 (1.04–1.24) 0.007 0.5348 1.72   10
26
MTCH2 rs4752856 T (0.37) 1.12 (1.03–1.23) 0.009 0.5257 1.10   10
27
MC4R rs17782313 C (0.26) 1.11 (1.00–1.22) 0.042 0.5293 1.04   10
26
NEGR1 rs2815752 A (0.58) 1.10 (1.01–1.20) 0.028 0.5263 2.21   10
27
GNPDA2 rs10938397 G (0.37) 1.10 (1.00–1.20) 0.045 0.5157 2.45   10
28
TMEM18 rs6548238 A (0.82) 1.10 (0.98–1.22) 0.095 0.5278 7.00   10
28
KCTD15 rs11084753 G (0.63) 1.05 (0.96–1.14) 0.33 0.5087 3.57   10
27
PCSK1 rs6235 C (0.30) 1.05 (0.96–1.16) 0.30 0.5221 1.20   10
26
GBS (SD units) – – 1.13 (1.06–1.21) ,0.001 0.5752 2.00   10
25
GBS (5th versus 1st quintile) – – 1.40 (1.14–1.72) 0.002  ––
For the calculation of odds ratios (OR), obesity is deﬁned according to WHO (13,14). The area under the receiver operator characteristic curves
(ROCAUC) reported in the table are unadjusted. PROCAUC is the signiﬁcance level of the test for difference between the ROCAUC for each single
nucleotidepolymorphism (SNP) or the geneticburden score (GBS) versustheROCAUC for all SNPs (0.6147). These comparisons test theability of each
genetic predictor to discriminate between 353 obese (BMI .30 kg/m
2) and 1370 normal weight (BMI 18.5–24.9 kg/m
2) individuals. As described in the
results, gene–sex interactions were observed for obesity (P ¼ 0.02) at the MC4R locus.  P-value obtained by direct comparison of ﬁfth versus ﬁrst GBS
quintiles, adjusted for age and sex (n ¼ 1325).
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underlie the interaction effects observed here is difﬁcult to
quantify owing to a lack of detailed information on these
parameters.
Although during recent years the prevalence of obesity in
northern Sweden has been rising at a similar rate to its
European neighbors, the incidence of type 2 diabetes has
remained relatively stable in Sweden during this time (11).
However, the present study suggests that the genetic basis of
obesity in people from Va ¨sterbotten is similar to other geo-
graphic populations. Thus, studies which seek to determine
the mechanisms that protect this population against the
diabetes-inducing effects of obesity might yield important
insights into diabetes prevention that are relevant to other popu-
lations. In this context, studies focusing on gene–environment
interactions may help elucidate why the relationship between
obesity and diabetes differs between populations.
In conclusion, we have replicated the genotype associations
with obesity for six (FTO rs1121980, SH2B1 rs7498665,
MTCH2 rs4752856, MC4R rs17782313, NEGR1 rs2815752,
GNPDA2 rs10938397) of nine previously associated loci.
We also quantiﬁed the combined effect of these variants on
obesity risk and described the extent to which the associations
with obesity are attributable to increased total and regional
adipose mass. Furthermore, we illustrate the degree to which
these variants increase the risk of type 2 diabetes, showing
that this risk is largely dependent on BMI. These extensions
of the original ﬁndings provide further insight into the role
common genetic variation plays in human obesity and the
associated risk of metabolic disease. However, it is also
evident that the effect of these variants on obesity and type
2 diabetes risk is fairly modest. Thus, it is unlikely that in
its present form this information will add substantially to
current risk prediction algorithms for these diseases.
MATERIALS AND METHODS
Participants
The 4923 individuals included in this report were white
Swedish adults living within the county of Va ¨sterbotten in
northern Sweden who had participated in the Northern
Swedish Health and Disease Study (NSHED), a prospective
cohort study of common diseases of later life (12). Participant
characteristics are shown in Table 1. All living participants
provided written informed consent. Permission to undertake
genetic analyses in these materials was obtained from the
research ethics committee of Umea ˚ University.
Measures of obesity
Anthropometric measures were collected as part of NSHED by
trained research nurses using a protocol standardized across
study centers (12). Height and weight were measured using
a calibrated wall-mounted stadiometer and scales, respect-
ively. BMI was calculated as weight in kilograms divided by
height in meters-squared (kg/m
2). Obesity is deﬁned according
to WHO (13). In a subgroup of 2206 individuals, DEXA scans
were performed for the assessment of total and regional
adipose distribution (Lunar DPX-L, IQ, or Prodigy IV, GE
Lunar, WI, USA), the methods for which have been described
in detail previously (10). Brieﬂy, participants dressed in light-
weight clothing free of metallic parts, were instructed to lie ﬂat
on the DEXA table as the scanning arm passed over their
body. DEXA scanners were calibrated daily with body mass
phantoms according to the manufacturer’s protocols.
Diabetes diagnosis
To test whether the obesity variants were associated with type
2 diabetes, we genotyped 1038 people with clinically manifest
type 2 diabetes. The type 2 diabetes ascertainment procedures
included clinical chart review and an independent oral glucose
tolerance test as described in detail previously (15). Participant
characteristics are shown in Table 1.
Genetic analyses
DNA was extracted at the Medical Biobank in Umea ˚ from per-
ipheral white blood cells. Genomic DNA samples were sub-
sequently diluted to 4 ng/ml. Taqman MGB chemistry
(Applied Biosystems, Foster City, CA, USA) was used for
all genotyping assays in accordance with the recommended
protocol (16). Genotyping success and concordance rates
were .94% and .99% for all single nucleotide polymorph-
isms (SNPs), respectively.
Genetic burden score
A score summarizing the overall obesity burden conveyed by
each of the eight variants replicate by the GIANT consortium
was computed by weighting each variant [i.e. by multiplying
Figure 3. Unadjusted receiver-operating characteristic curve showing the
combined ability of the genetic burden score to discriminate between 353
obese (BMI .30 kg/m
2) and 1370 normal weight (BMI 18.5–24.9 kg/m
2)
individuals.
1494 Human Molecular Genetics, 2009, Vol. 18, No. 8the genotype at each locus by its per allele effect on BMI
reported in the original meta-analysis; see Table 4 for refer-
ence (6)] and then summing-up these values.
Statistical analysis
All statistical analyses were undertaken using the SAS soft-
ware (v9.1, SAS Institute, Cary, NC, USA). Haploview v4.0
(http://www.broad.mit.edu/mpg/haploview) was used to deter-
mine Hardy–Weinberg equilibrium (HWE). All genotypes
fulﬁlled HWE expectations (P . 0.01). Generalized linear
models were used to test genotype associations for continuous
outcome traits (i.e. height, weight, BMI and DEXA measures
of adiposity). Logistic regression was used to assess the
association between each variant and obesity or type 2 dia-
betes as binary variables deﬁned according to the deﬁnitions
of the World Health Organization and ADA (13,14). All
models were adjusted for age and sex and assumed an additive
mode of inheritance. For anthropometric outcome variables,
interaction tests were performed to determine whether the
genetic effects differed by sex. This was achieved by ﬁtting
a term for genotype (0,1,2)   sex (0,1) to the regression
models. For the models where obesity or type 2 diabetes
were the outcomes, the area under the ROCAUC for each
variant was calculated and compared with the ROCAUC
derived from a model including all genotypes simultaneously.
These analyses were performed using the methods described
by DeLong et al. (17).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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